Formulating erythropoietin-loaded sustained-release PLGA microspheres without protein aggregation

被引:60
作者
Geng, Yan [1 ]
Yuan, Weien [1 ]
Wu, Fei [1 ]
Chen, Jingle [1 ]
He, Mu [1 ]
Jin, Tuo [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200240, Peoples R China
基金
美国国家科学基金会;
关键词
Erythropoietin; Microspheres; Aggregation; Sustained-release;
D O I
10.1016/j.jconrel.2008.06.011
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
We report a simple method to microencapsulate erythropoietin (EPO, a protein easily denatured and antigenized by contact with water-organic solvent interfaces) into poly(lactic-co-glycolic acid) (PLGA) microspheres with minimal aggregation. This formulation process involved an aqueous-aqueous emulsion formed at reduced temperature. EPO was first dissolved in water together with dextran (MW=70,000) and polyethylene glycol (MW=8000), followed by a freezing process during which dextran separated out as the dispersed phase with EPO partitioned in preferentially. The frozen sample was then lyophilized to powder and washed with dichloromethane to remove the PEG continuous phase. Once loaded in the polysaccharide particles, 1-4 mu m in diameter, EPO gained resistance to organic solvents and was encapsulated into PLGA microspheres without significant aggregation (<2%). EPO released from the composite PLGA microspheres in a sustained-release manner with minimal burst (<20% at the first day) and incomplete (<20%) release. Single injection of these EPO-loaded PLGA microspheres to mice resulted in a red blood cell elevation equivalent to twelve injections of the solution formulation. An ELISA assay suggested that the mice injected with the EPO-loaded PLGA microspheres did not develop anti-EPO IgG more than those given solution form EPO. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:259 / 265
页数:7
相关论文
共 32 条
[1]   Detection and prevention of protein aggregation before, during, and after purification [J].
Bondos, SE ;
Bicknell, A .
ANALYTICAL BIOCHEMISTRY, 2003, 316 (02) :223-231
[2]   Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation [J].
Breen, ED ;
Curley, JG ;
Overcashier, DE ;
Hsu, CC ;
Shire, SJ .
PHARMACEUTICAL RESEARCH, 2001, 18 (09) :1345-1353
[3]  
*BRIT STAND I, 1958, GLOSS TERMS REL POWD
[4]   Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: Implications for the mechanism of protein stabilization in the solid state [J].
Chang, LQ ;
Shepherd, D ;
Sun, J ;
Tang, XL ;
Pikal, MJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (07) :1445-1455
[5]   Polymeric growth factor delivery strategies for tissue engineering [J].
Chen, RR ;
Mooney, DJ .
PHARMACEUTICAL RESEARCH, 2003, 20 (08) :1103-1112
[6]  
Christophers S. R., 1907, Sci Mem Med Ind Calcutta N Ser, VNo. 28
[7]   Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres [J].
Cleland, JL ;
Jones, AJS .
PHARMACEUTICAL RESEARCH, 1996, 13 (10) :1464-1475
[8]   Normalization of hemoglobin level in patients with chronic kidney disease and anemia [J].
Drueke, Tilman B. ;
Locatelli, Francesco ;
Clyne, Naomi ;
Eckardt, Kai-Uwe ;
Macdougall, Iain C. ;
Tsakiris, Dimitrios ;
Burger, Hans-Ulrich ;
Scherhag, Armin .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (20) :2071-2084
[9]  
Duplay D., 2005, PHYS DESK REFERENCE
[10]   Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin [J].
Egrie, JC ;
Dwyer, E ;
Browne, JK ;
Hitz, A ;
Lykos, MA .
EXPERIMENTAL HEMATOLOGY, 2003, 31 (04) :290-299